[{"address1": "3020 Carrington Mill Blvd.", "address2": "Suite 475", "city": "Morrisville", "state": "NC", "zip": "27560", "country": "United States", "phone": "212 554 4484", "fax": "212 554 4531", "website": "https://www.tgtherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. The company was incorporated in 1993 and is based in Morrisville, North Carolina.", "fullTimeEmployees": 352, "companyOfficers": [{"maxAge": 1, "name": "Mr. Michael S. Weiss Esq.", "age": 58, "title": "Chairman, CEO & President", "yearBorn": 1966, "fiscalYear": 2024, "totalPay": 1970938, "exercisedValue": 0, "unexercisedValue": 26229992}, {"maxAge": 1, "name": "Mr. Sean A. Power CPA", "age": 42, "title": "CFO, Corporate Secretary & Treasurer", "yearBorn": 1982, "fiscalYear": 2024, "totalPay": 780600, "exercisedValue": 0, "unexercisedValue": 8840500}, {"maxAge": 1, "name": "Ms. Jenna  Bosco", "title": "Senior Vice President of Corporate Communications", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Adam  Waldman", "title": "Chief Commercialization Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 9, "boardRisk": 10, "compensationRisk": 10, "shareHolderRightsRisk": 3, "overallRisk": 9, "governanceEpochDate": 1748736000, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 37.67, "open": 37.57, "dayLow": 37.075, "dayHigh": 37.69, "regularMarketPreviousClose": 37.67, "regularMarketOpen": 37.57, "regularMarketDayLow": 37.075, "regularMarketDayHigh": 37.69, "payoutRatio": 0.0, "beta": 1.939, "trailingPE": 148.34, "forwardPE": 38.231956, "volume": 927404, "regularMarketVolume": 927404, "averageVolume": 2201291, "averageVolume10days": 1532960, "averageDailyVolume10Day": 1532960, "bid": 31.91, "ask": 42.29, "bidSize": 1, "askSize": 1, "marketCap": 5887429120, "fiftyTwoWeekLow": 16.65, "fiftyTwoWeekHigh": 46.48, "priceToSalesTrailing12Months": 15.23717, "fiftyDayAverage": 36.5875, "twoHundredDayAverage": 32.984524, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 5226260480, "profitMargins": 0.10132, "floatShares": 135060602, "sharesOutstanding": 158755008, "sharesShort": 23697171, "sharesShortPriorMonth": 22571826, "sharesShortPreviousMonthDate": 1747267200, "dateShortInterest": 1749772800, "sharesPercentSharesOut": 0.14930001, "heldPercentInsiders": 0.09738, "heldPercentInstitutions": 0.63244, "shortRatio": 13.21, "shortPercentOfFloat": 0.19520001, "impliedSharesOutstanding": 161259008, "bookValue": 1.634, "priceToBook": 22.695839, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1743379200, "netIncomeToCommon": 39150000, "trailingEps": 0.25, "forwardEps": 0.97, "lastSplitFactor": "100:5625", "lastSplitDate": 1335744000, "enterpriseToRevenue": 13.526, "enterpriseToEbitda": 87.296, "52WeekChange": 0.7435355, "SandP52WeekChange": 0.1116153, "quoteType": "EQUITY", "currentPrice": 37.085, "targetHighPrice": 53.0, "targetLowPrice": 11.0, "targetMeanPrice": 41.2, "targetMedianPrice": 46.0, "recommendationKey": "none", "numberOfAnalystOpinions": 5, "totalCash": 276240000, "totalCashPerShare": 1.894, "ebitda": 59868000, "totalDebt": 254583008, "quickRatio": 2.911, "currentRatio": 4.023, "totalRevenue": 386385984, "debtToEquity": 107.288, "revenuePerShare": 2.657, "returnOnAssets": 0.0726, "returnOnEquity": 0.19703, "grossProfits": 337800000, "freeCashflow": -87638496, "operatingCashflow": -61025000, "revenueGrowth": 0.904, "grossMargins": 0.87426, "ebitdaMargins": 0.15494001, "operatingMargins": 0.071339995, "financialCurrency": "USD", "symbol": "TGTX", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "regularMarketChangePercent": -1.55296, "regularMarketPrice": 37.085, "cryptoTradeable": false, "exchange": "NCM", "messageBoardId": "finmb_143627354", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "marketState": "CLOSED", "shortName": "TG Therapeutics, Inc.", "longName": "TG Therapeutics, Inc.", "corporateActions": [], "postMarketTime": 1752278054, "regularMarketTime": 1752264000, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1272893400000, "postMarketChangePercent": 0.0407237, "postMarketPrice": 37.1001, "postMarketChange": 0.0151024, "regularMarketChange": -0.584999, "regularMarketDayRange": "37.075 - 37.69", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 2201291, "fiftyTwoWeekLowChange": 20.435, "fiftyTwoWeekLowChangePercent": 1.2273273, "fiftyTwoWeekRange": "16.65 - 46.48", "fiftyTwoWeekHighChange": -9.395, "fiftyTwoWeekHighChangePercent": -0.20212996, "fiftyTwoWeekChangePercent": 74.35355, "earningsTimestamp": 1746442800, "earningsTimestampStart": 1754310600, "earningsTimestampEnd": 1754656200, "earningsCallTimestampStart": 1746448200, "earningsCallTimestampEnd": 1746448200, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": 0.25, "epsForward": 0.97, "epsCurrentYear": 0.95197, "priceEpsCurrentYear": 38.95606, "fiftyDayAverageChange": 0.49749756, "fiftyDayAverageChangePercent": 0.013597473, "twoHundredDayAverageChange": 4.1004753, "twoHundredDayAverageChangePercent": 0.12431513, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "displayName": "TG Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-07-12"}]